

### 2017 shortlisting letter campaign to industry: scope and expected outcome

ECHA Webinar - How are substances screened and shortlisted?

Giovanni Bernasconi ACROSS team ECHA, 14 February 2017



### Content

- Letter campaign on shortlisted substances
  - Aim
  - Statistics and overview of updates
  - Industry's feedback
- Reasons for shortlisting and how you can influence the outcome of screening
- Expected outcome and next steps

# Letter campaign on shortlisted substances




### Aim of letter campaign

- Inform Registrants of shortlisting, i.e. substances are under authorities' scrutiny
- Invite Registrants to review the registration dossiers and update them before manual screening starts



### **Statistics and overview of updates/1**


- Dossiers updated for approximately 50% of substances within ~6 months
- A report monitoring the updates is shared with the MSCAs monthly
- Updates not received in time for manual screening will be valuable if/when further regulatory action starts





### **Statistics and overview of updates/2**

### 2016 letter campaign: main reasons for updating





### **Industry's feedback**

- Several Registrants appreciated ECHA's transparency, the campaign and submitted a dossier update
- First letter campaign (2015):
  - timing of letters-sending not optimal
  - content of letters 'too generic'
  - not clear deadline for updating
- Second letter campaign (2016):
  - timelines for dossier updating too tight
  - need to better understand the reasons for shortlisting





### **Letter campaign – main improvements**

- Earlier letters-sending same week shortlist is released to Member States
- More targeted letters more information on the reasons for shortlisting is provided in the letters
  - Definition Document to be consulted for further information
- *Timeline for updating* Tight deadline, however...
  - a report monitoring the updates is shared with the MSCAs monthly
  - updates not received in time for manual screening will be valuable if/when further regulatory action starts

## Reasons for shortlisting and how you can influence the outcome of screening



### **Common screening approach** - to identify substances of concern

- Selection of substances based on a combination of (potential) hazard information and use/exposure information
- Priority for shortlisting is given to those substances having:

A high tonnage <u>for</u> **wide dispersive uses** <u>within</u> the scope of regulatory action (Substance Evaluation, Classification and Labelling, authorisation, restriction)

• What does that mean?



### **Definition of wide dispersive use**

- Wide dispersive:
  - widespread (used at many sites, by many users) <u>and</u>
  - potential for release to environment and/or potential for human exposure
- See also R12 Guidance and Screening Definition Document



### What does it mean for screening?

- A substance (potentially) hazardous with high tonnage <u>for</u> wide dispersive uses <u>within</u> the scope of regulatory action will be **prioritised** for further work
- <u>But also</u> that the following (potentially) hazardous substances will be parked for the time being (**low priority**):
  - Substances with <u>no wide dispersive uses</u>
  - Substances with <u>no uses</u> in the scope of regulatory action (Substance Evaluation, Classification and Labelling, authorisation, restriction)



## Current (mass) screening approach

- At present, no use-specific tonnage information • available
- Potentially relatively high number of false positives and • negatives
- E.g. two substances with similar overall tonnage •

#### Substance A:

- Several intermediate uses, high tonnage
- small tonnage

### Substance B:

- One intermediate use, low tonnage
- One wide dispersive use, Several wide dispersive uses, high tonnage



echa.europa.eu



# **Reasons for shortlisting: Definition document**

 More information on the criteria applied could be found in a Definition Document uploaded on ECHA website. LINK:

http://echa.europa.eu/documents/10162/19126370/screening\_definition\_d ocument\_en.pdf



 Please consult this document if you have questions with the reasons why your substance was shortlisted!



# **Review of your dossier: hazard information**

- Updated information on potential hazard(s) could influence the manual screening/further processes
- Hazard. Look critically into your data and the <u>potential</u> hazard(s) indicated in the letter
  - Is there a risk uncovered?
  - Is your data robust enough (validity of study/WoE/RA) to clarify this potential risk?
  - Strengthen your reasoning or make a Testing Proposal



## **Review of your dossier: uses information**

- **Uses.** ECHA advises you to:
  - review if the uses are still up to date
  - provide, to the extent possible, the tonnage per use
  - ensure uses are described using a sufficiently informative use name
  - cover the whole life-cycle of the substance
- Updated info on uses could influence the manual screening outcome and also the follow up processes
  - Resources from both authorities and industry should focus on those substances that matter for which uses are of relevance from a regulatory risk management perspective



### Review of your dossier: uses information to summarise

### Report and/or update information in your registration dossier on tonnage, use and exposure information, in particular

- For substances (potentially) hazardous to human health (e.g. CMR, S, ED) and with most uses
  - exempted from REACH and CLP processes (e.g. intermediates) <u>and/or</u>
  - taking place under strictly controlled conditions <u>and/or</u>
  - taking place in a limited number of industrial sites
- For substances (potentially) hazardous to the environment (PBT, ED) and with most uses
  - exempted from REACH and CLP processes (e.g. intermediates) <u>and/or</u>
  - taking place under strictly controlled conditions

### **Expected outcome and next steps**






## **Expected outcome and next steps/1**

- Shortlist opened for booking on 27 January 2017 and manual screening to start 17 March 2017
- Up-to-date information will help the Member State authorities better assess whether the concern indicated by the screening is confirmed, and whether regulatory action is still needed
- Consider updating your dossier by 17 March 2017



## **Expected outcome and next steps/2**

- Results of the manual screening is not communicated directly to industry
- Companies can check the status of their substance through the Search for chemicals available on ECHA's homepage.





## **Additional information**

In case of further questions with the common screening and the letter campaign, please consult:

• ECHA common screening webpage

http://echa.europa.eu/addressing-chemicals-of-concern/substances-of-potentialconcern/screening

- Updated definition document to support common screening http://echa.europa.eu/documents/10162/19126370/screening\_definition\_document\_en.pdf
- FAQ on screening and shortlisting

https://echa.europa.eu/support/qas-support/browse/-/qa/70Qx/view/scope/REACH/Screening+of+substances+of+potential+concern

• This webinar material

https://echa.europa.eu/-/how-are-substances-screened-and-shortliste-1

• Links provided in the annexes to the letters



## Conclusions

- Letter campaign gives you the possibility to clarify the potential hazard and use profile of your substances
- Up to date and complete information might influence the MSCAs manual screening or any further process
- Review your dossier and consider updating it **by 17 March**



Thank you!

Subscribe to our news at echa.europa.eu/subscribe

Follow us on Twitter @EU\_ECHA

Follow us on Facebook Facebook.com/EUECHA



### Webinar agenda

### How are substances screened and shortlisted?

# 10:40 – 11:00 2017 shortlisting letter campaign to industry: scope and expected outcome

#### Giovanni Bernasconi , ECHA

- Aim of letter campaign, changes from previous campaign
- How registrants can influence the screening outcome by updating their dossiers

#### **11:00 Q&A session** – *All*

- Questions and answers in writing
- Please send your questions until 11:45 at the latest
- Recurring issues will be addressed in the Q&A published on the ECHA website
- Link to the Q&A: <u>https://echa.europa.eu/support/qas-support/browse/-</u> /qa/70Qx/view/scope/REACH/Screening+of+substances+of+potential+concer <u>n</u>